Biocon will hold a meeting of the Board of Directors of the Company on 30 January 2025.Powered by Capital Market - Live News

Biocon announced that the company and it European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU). The approval is for the generic versions of Victoza� to treat Type-2 Diabetes and Saxenda� used in the treatment of weight management. Powered by Capital Market - Live News

Net loss of Biocon reported to Rs 16.00 crore in the quarter ended September 2024 as against net profit of Rs 125.60 crore during the previous quarter ended September 2023. Sales rose 4.49% to Rs 3545.00 crore in the quarter ended September 2024 as against Rs 3392.60 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3545.003392.60 4 OPM %19.3321.15 - PBDT492.30627.60 -22 PBT72.40238.30 -70 NP-16.00125.60 PL Powered by Capital Market - Live News

Biocon will hold a meeting of the Board of Directors of the Company on 30 October 2024.Powered by Capital Market - Live News

Biocon Biologics (BBL), a subsidiary of Biocon, today announced the successful pricing of Biocon Biologics` debut USD 800 million (Rs 6676.3 crore) senior secured Notes due 2029 at a coupon of 6.67%. The Bonds will be issued by Biocon Biologics Global plc which is a wholly owned subsidiary of BBL and will be backed by a strong security package. The Bonds are expected to be rated BB by both S&P and Fitch and will be listed on the Singapore Stock Exchange. The transaction is expected to settle on October 09, 2024 subject to customary closing conditions.Additionally, Biocon Biologics has entered into a commitment agreement for a new syndicated debt facility. The proceeds of the Bonds, together with the new syndicated debt facility being raised, will be used to substantially re-finance existing debt of USD 1.1 billion (Rs 9346.8 crore) which will help improve the Company`s liquidity profile, provide financial flexibility and opportunity to re-invest the cash into the business.Powered by Capital Market - Live News